Is empirical antibiotic treatment correlated to outcome in microbiology-negative pleural infection?

Christian Niels Meyer (Roskilde, Denmark), Christian Niels Meyer, Karin Armbruster

Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Christian Niels Meyer (Roskilde, Denmark), Christian Niels Meyer, Karin Armbruster. Is empirical antibiotic treatment correlated to outcome in microbiology-negative pleural infection?. Eur Respir J 2016; 48: Suppl. 60, 2652

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
An review of infection rates of invasive pleural procedures
Source: International Congress 2016 – Pleural diseases
Year: 2016


Could the initial use of antipseudomonal agents improve the prognosis for non-hospital acquired pneumonia?
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013

Modification of empirical antibiotic therapy in community acquired pneumonia
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014


Pulmonary actinomycosis: Successful treatment with oral antibiotics
Source: Annual Congress 2013 –Interesting cases of respiratory infections
Year: 2013


Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP)
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013


Pleural infection: moving from treatment to prevention
Source: Eur Respir Monogr 2020; 87: 155-171
Year: 2020


Anti-tuberculosis drug concentrations and treatment outcomes in patients with both tuberculosis and HIV infection
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Year: 2013

Risk factors associated to surgical treatment of parapneumonic effusion and empyema
Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections
Year: 2013


Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016


Could the early administration of antibiotics before admission improve the prognosis of pneumonia?
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015

Study of pleural empyema evolution depending on drainage size used
Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Year: 2013


Factors affecting treatment success in community acquired pneumonia (CAP)
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013


Influence of long antibiotic therapy of lower respiratory tract infection (LRTI) on cytological characteristics of sputum
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013


Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016


Does standardized medical treatment for parapneumonic empyema (PE) in children reduces the need for surgical intervention?
Source: Annual Congress 2013 –Pulmonary infection in children: diagnosis and long-term effects
Year: 2013


Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP)
Source: International Congress 2014 – Respiratory infections: inflammation and treatment
Year: 2014


Rifampicin-resistant TB on Gene Xpert: What is the best empiric combination treatment while awaiting cultures?
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015


Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016


Evaluation of drug induced liver injury due to anti tuberculous drugs in directly observed daily therapy
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016